The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial.’ (Abstract number: 0470) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is known about the efficacy and safety of tocilizumab in the treatment of giant cell arteritis (GCA)? (0:16)
- Could you give us a brief overview of the GUSTO trial and its findings? (1:08)
- What were the objectives of the current analysis of the GUSTO trial? (2:12)
- What were the findings of this analysis? (2:41)
- Why was the relapse rate lower than those reported in earlier clinical trials? (3:12)
Disclosures: Lisa Christ discloses receiving grant/ research support from F. Hoffmann-La Roche, Gilead Sciences, and Pfizer; serving on advisory boards for Bristol-Myers Squibb and Novartis; and other financial support from F. Hoffmann-La Roche, Bristol-Myers Squibb, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry
Filmed in coverage of the ACR Convergence 2022.
